Xizang Haisco Pharmaceutical Group Co Ltd (002653.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100001BC7

Price
59.38 CNY
Market cap
66.50 bn CNY
P/E (2025)
256.19
P/S (2025)
15.16
Dividend yield
1.34 %
Net margin
5.92 %
Return on equity (ROE)
6.05 %
Return on assets (ROA)
3.70 %

Xizang Haisco Pharmaceutical Group Co Ltd financials

Fiscal year20242025
Revenue3.72 bn CNY4.39 bn CNY
Gross profit2.66 bn CNY3.12 bn CNY
Operating income507.45 m CNY323.84 m CNY
EBIT262.03 m CNY306.11 m CNY
Net income395.46 m CNY259.58 m CNY
Diluted EPS – continuing operations0.35 CNY0.23 CNY

Full history since 2008, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Xizang Haisco Pharmaceutical Group Co Ltd

Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research collaboration with Eli Lilly and Company to develop medicines across multiple therapeutic areas. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Shannan, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.